1-4 of 4
Martine Chamuleau, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First Report on a Successful Screening Program for MYC Rearrangements and a Prospective Clinical Trial Based on MYC Rearrangement in Newly Diagnosed DLBCL Patients in the Netherlands

Martine Chamuleau, MD PhD, Marcel Nijland, MD, Niek Lamers, Nathalie Hijmering, Dana Chitu, Josée Zijlstra, MD, Otto Visser, MDPhD, Josephine M. Vos, MD, Henriette Berenschot, MD, Rinske Boersma, MD, Marie Jose Kersten, MD PhD, Daphne de Jong, Prof Dr
Journal: Blood
Blood (2017) 130 (Supplement 1): 4144.
https://doi.org/10.1182/blood.V130.Suppl_1.4144.4144
Published: 2017
Journal Articles

Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial

Arnon P. Kater, MD, Marinus H.J. H.J. Van Oers, MD PhD, Yvette Norden, Roberto D. Liu, Martin R. Schipperus, Martine Chamuleau, MD PhD, Marcel Nijland, MD, Jeanette K. Doorduijn, MD PhD, Michel van Gelder, MDPhD, Mels Hoogendoorn, MDPhD, Fransien Croon-de Boer, Shulamit Wittebol, Martijn Kerst, MDPhD, Willem Marijt, Ward Posthuma, MD PhD, Reinier Raymakers, MDPhD, Ron Schaafsma, MDPhD, Johan Dobber, Sabina Kersting, MDPhD, Mark-David Levin
Journal: Blood
Blood (2017) 130 (Supplement 1): 4328.
https://doi.org/10.1182/blood.V130.Suppl_1.4328.4328
Published: 2017
Journal Articles

Potent Ex Vivo Anti-Tumor Activity in Relapsed Refractory Multiple Myeloma Using Novel DR5-Specific Antibodies with Enhanced Capacity to Form Hexamers upon Target Binding

Hilma J van der Horst, Marije B Overdijk, Esther CW Breij, Martine Chamuleau, MD PhD, Henk M Lokhorst, Tuna Mutis, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1835.
https://doi.org/10.1182/blood.V130.Suppl_1.1835.1835
Published: 2017
Journal Articles

High Expression of Decoy Receptor TRAIL-R3 on AML Blasts Is Associated to Shortened Overall Survival. TRAIL-R3 Induced Apoptosis Resistance Can Be Overcome by Specifically Targeting TRAIL-R2 in Vitro

Martine Chamuleau, MD, Linda van Dreunen, S.M.G. Jirka, A. Zevenbergen, G. Ossenkoppele, MD, PhD, Arjan A van de Loosdrecht, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2946.
https://doi.org/10.1182/blood.V112.11.2946.2946
Published: 2008